Head-to-head · WeighScore
Royal Medical Center vs Zealthy
The verdict
Royal Medical Center takes it — 49.4/100 to 46.7/100.
Royal Medical Center grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Royal Medical Center is a physician-led nationwide telehealth practice centered on hormone therapy that also offers a compounded tirzepatide weight-loss program (no semaglutide).
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Royal Medical Center | Zealthy |
|---|---|---|
| WeighScore | 49.4/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #492 | #496 |
| Semaglutide | Not disclosed | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $450/mo (2.5 mg dose, compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #492 · C
Strengths
- Physician founder Dr. Dagoberto Rodriguez, MD — Emory residency, former Coral Springs Medical Center chairman, U Miami faculty
- Tirzepatide pricing fully itemized by dose tier ($450 / $650 / $800 / $1,100) — more transparent than 'starting at' floors
- All-inclusive pricing bundles medication, supplies, injections, lab monitoring, and physician follow-ups
- Broad catalog (HRT, TRT, peptides, ED, hair, vitamins) reflects an established multi-program clinic
- Florida physician with 30+ years of practice — a strong physician-led care signal
Where it loses points
- Operating legal entity not disclosed — only the 'Royal Medical Center' brand surfaced
- Pharmacy partner not named — buyers can't verify licensure or 503A/503B status
- No LegitScript badge displayed
- States served not enumerated — site says 'nationwide' with no state list
- Headline 'starting at $116/mo' conflicts with the actual $450/mo tirzepatide floor
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.